Onxeo S.A.: High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie : vimarsana.com

Onxeo S.A.: High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie

Regulatory News: Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North1: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage

Related Keywords

Luxembourg , Paris , France General , France , Copenhagen , Køavn , Denmark , Orsay , French , Catherine Goupillon , Marie Curie , Marie Dutreix , Emmanuel Huynh , Arthur Rouill , Shefali Agarwal , Kriibskrank Kanner , Le Tourneau , Onxeo Sa Euronext , Institut Curie , Company Group , Nasdaq , Regulatory News , Euronext Growth , Nasdaq First , High Grade Glioma , Grade Gliomas , Chief Executive Officer , Professor Fran , European Fight Kids , Carnot Curie , Euronext Paris , First North Growth , Innovative Therapies , Kids Cancer , Nasdaq First North , Onxeo , Igh , Rade , Lioma , Elapse , Hildren , Nnounces , Nrollment , Irst , Atient , Hase , Linical , Tudy , Onducted , Uropean , Tcc , Onsortium , Ponsored , Nstitut , Urie ,